Glimepirid Stada

Glimepirid Stada is a prescription oral tablet that contains glimepiride, a second‑generation sulfonylurea used to lower blood glucose in adults with type 2 diabetes mellitus. Distributed in the European Union, the product’s strength varies by market and it is taken by mouth under medical supervision. The drug belongs to the oral hypoglycemic therapeutic class and promotes insulin release from pancreatic β‑cells as part of a comprehensive diabetes management plan.

Glimepirid Stada is indicated for the oral treatment of type 2 diabetes mellitus when diet, exercise, and other non‑pharmacologic measures are insufficient to achieve glycemic control.

- As monotherapy in patients newly diagnosed with type 2 diabetes. - In combination with metformin when metformin alone does not achieve target HbA1c. - As part of a fixed‑dose combination regimen with other oral antidiabetic agents. - For patients who can tolerate sulfonylureas and have adequate renal function. - To help maintain fasting and post‑prandial glucose levels within recommended ranges.

Glimepirid Stada may cause a range of adverse effects, most of which are related to its insulin‑stimulating action and are categorized by frequency and severity.

Common: - Mild hypoglycemia, which may present as shakiness, sweating, or irritability, especially when meals are skipped or delayed. - Gradual weight gain, often modest, due to increased insulin activity and reduced glucose excretion. - Gastrointestinal discomfort such as nausea, abdominal pain, or dyspepsia. - Headache or dizziness, typically transient and mild.

Serious: - Severe hypoglycemia that can lead to loss of consciousness, seizures, or the need for emergency medical assistance. - Allergic reactions including skin rash, pruritus, angio‑edema, or, in rare cases, anaphylaxis. - Hematologic abnormalities such as leukopenia, thrombocytopenia, or other blood cell count changes that may require monitoring.

Before initiating Glimepirid Stada, healthcare providers should evaluate several clinical factors to ensure safe and effective use.

- Assess renal and hepatic function, as impairment may require dose adjustment or alternative therapy. - Review patient history for prior sulfonylurea hypersensitivity or severe hypoglycemia episodes. - Consider age, especially in elderly patients who may be more susceptible to hypoglycemia. - Evaluate concomitant use of other glucose‑lowering agents to avoid additive hypoglycemic risk. - Advise patients to maintain regular meal patterns and avoid excessive alcohol consumption. - Monitor blood glucose regularly, particularly during treatment initiation and dose changes.

Glimepirid Stada can interact with other medicines, affecting blood glucose control or increasing the risk of adverse events.

Avoid: - Concurrent use with other sulfonylureas or meglitinides, which may cause additive hypoglycemia. - Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone) that can significantly increase glimepiride plasma levels. - High‑dose salicylates or NSAIDs that may potentiate hypoglycemic effects.

Use with caution: - Beta‑blockers, which can mask hypoglycemia symptoms. - Thiazide diuretics, which may impair glucose tolerance. - Alcohol, especially in excess, as it can enhance hypoglycemia risk.